F2R and familial pancreatic carcinoma: In conclusion, this work showed that PAR1 can promote the CSC-like properties of pancreatic cancer by activating the FAK/PI3K/AKT pathway. As a PAR1 inhibitor, doxycycline can inhibit the CSC-like properties of pancreatic cancer cells targeting the PAR1/FAK/PI3K/AKT pathway and can enhance the therapeutic effect of 5-FU (Figure 7I).